Jan J Molenaar

List of Publications by Year
in descending order

42 papers	4,586 citations	361413 20 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	7642 citing authors

#	Article	IF	Citations
1	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
2	Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature, 2012, 483, 589-593.	27.8	775
3	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
4	Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature Genetics, 2017, 49, 1261-1266.	21.4	362
5	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics, 2012, 44, 1199-1206.	21.4	336
6	TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nature Genetics, 2015, 47, 1411-1414.	21.4	313
7	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11, 1310.	12.8	183
8	Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12968-12973.	7.1	147
9	Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma. Cancer Research, 2008, 68, 2599-2609.	0.9	141
10	Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes and Cancer, 2003, 36, 242-249.	2.8	79
11	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Science Advances, 2021, 7, .	10.3	78
12	Copy number defects of G1â€€cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes and Cancer, 2012, 51, 10-19.	2.8	57
13	Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. European Journal of Cancer, 2014, 50, 628-637.	2.8	57
14	Pulmonary interstitial glycogenosis in identical twins. Pediatric Pulmonology, 2005, 40, 362-366.	2.0	51
15	MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. Cancer Letters, 2015, 366, 123-132.	7.2	51
16	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 2015, 21, 5100-5109.	7.0	49
17	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget, 2015, 6, 35770-35781.	1.8	37
18	Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica, 2015, 100, e132-e136.	3.5	29

#	Article	IF	Citations
19	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget, 2015, 6, 18558-18576.	1.8	26
20	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Reports, 2021, 36, 109568.	6.4	25
21	Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. European Journal of Cancer, 2017, 75, 63-72.	2.8	23
22	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research, 2017, 23, 6629-6639.	7.0	23
23	DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLoS ONE, 2015, 10, e0145744.	2.5	22
24	The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development. Cancers, 2021, 13, 4324.	3.7	22
25	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatric Blood and Cancer, 2020, 67, e28061.	1.5	21
26	Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Scientific Reports, 2020, 10, 17667.	3.3	20
27	Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma. Journal of Molecular Diagnostics, 2015, 17, 43-52.	2.8	19
28	Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
29	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. Molecular Cancer Therapeutics, 2021, 20, 1462-1468.	4.1	14
30	Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells. Journal of Biotechnology, 2021, 338, 71-80.	3.8	14
31	Î³-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget, 2016, 7, 62799-62813.	1.8	12
32	Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses. European Journal of Cancer, 2021, 142, 1-9.	2.8	11
33	Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies. Journal of Personalized Medicine, 2021, 11, 869.	2.5	11
34	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies. European Journal of Cancer, 2022, 162, 107-117.	2.8	11
35	Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics. Cancer Science, 2022, 113, 2167-2178.	3.9	8
36	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. European Journal of Cancer, 2020, 130, 168-181.	2.8	7

#	Article	IF	Citations
37	Î±Î²-T Cells Engineered to Express Î³Î´-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. Journal of Personalized Medicine, 2021, 11, 923.	2.5	5
38	High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling. Biomedicines, 2022, 10, 638.	3.2	4
39	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. European Journal of Cancer, 2022, 170, 196-208.	2.8	4
40	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 92, 144-148.	2.8	2
41	Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	1
42	Towards Personalized Therapy in Pediatric Acute Lymphoblastic Leukemia; Ras Mutations and Prednisolone Resistance. Blood, 2014, 124, 372-372.	1.4	0